Ginkgo Bioworks

Programs cells to produce custom organisms

Boston, Massachusetts, United States

About Ginkgo Bioworks

Ginkgo Bioworks specializes in biotechnology by using advanced cell programming technology to create custom organisms that can produce various products, including food ingredients, fragrances, and therapeutics. Their platform allows them to design and grow these organisms, effectively turning cells into small factories that generate valuable compounds. Ginkgo collaborates with a wide range of clients, such as companies in the food and beverage sector, pharmaceuticals, agriculture, and biosecurity, to develop tailored biological solutions. This collaborative approach sets them apart from competitors, as they focus on partnerships to drive innovation and ensure a steady revenue stream through service fees, milestone payments, and royalties. The company's goal is to be a leader in the biotechnology field by providing custom solutions that meet the specific needs of their partners.

Boston, MassachusettsHeadquarters
2009Year Founded
$1,524.7MTotal Funding
IPOCompany Stage
Food & Agriculture, Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Unlimited paid time off
Comprehensive health and parental leave benefits
Flexible work options
Commuter benefits
State-of-the-art labs, work spaces, and conference rooms
Competitive 401K contribution

Risks

Competition from Phytolon threatens Ginkgo's market share in food ingredients.
Lesaffre's acquisition of Altar may intensify competition in biotechnology.
Fluctuating fertilizer prices could impact Ginkgo's agricultural projects.

Differentiation

Ginkgo Bioworks leverages advanced cell programming to create custom organisms for diverse industries.
The company collaborates with industry leaders like Moderna and Cronos Group for innovative solutions.
Ginkgo's platform enables the design of organisms for food, pharmaceuticals, and biosecurity.

Upsides

Partnership with Carnegie Mellon boosts Ginkgo's presence in bioelectronic disease treatment.
Acquisition of StrideBio's assets expands Ginkgo's gene therapy capabilities.
Collaboration with NOVUS International enhances sustainable solutions in animal agriculture.